A man-made version of creatine called cyclocreatine uses the same doorway into cells and turns off the creatine-making enzyme in a similar way, just needing higher amounts to have the same effect.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Establish the overall efficacy and safety profile of cyclocreatine across preclinical and clinical studies.
A systematic review of all animal and human studies on cyclocreatine, including pharmacokinetics, AGAT suppression, and toxicity, with meta-analysis of effect sizes and adverse events.
Determine clinical effectiveness of cyclocreatine in modulating creatine metabolism.
A double-blind RCT in 80 patients with GAMT deficiency, comparing cyclocreatine vs placebo for 6 months, measuring GAA levels, brain creatine, and neurodevelopmental outcomes.
Track long-term effects of cyclocreatine on creatine regulation.
A prospective cohort of 100 patients with creatine metabolism disorders treated with cyclocreatine, monitoring AGAT expression, creatine levels, and clinical status over 3 years.
Compare molecular responses to cyclocreatine between responders and non-responders.
A case-control study of 30 cyclocreatine responders vs 30 non-responders, matched for diagnosis, measuring CrT function and intracellular accumulation.
Provide initial human evidence of cyclocreatine's biological activity.
A case series of 5 patients with GAMT deficiency treated with cyclocreatine, documenting changes in GAA and clinical status.